Postponement of public data for six months is justified by slow rollout of CMS rules, they say
The pharma industry, among other life sciences firms, has been busy for most of this year preparing its reports to CMS on payments made to prescribers and some of their hospital affiliations. But over on the physicians’ side, near-panic seems to be setting in as the Sept. 30 date for public release of the spending data approaches. A letter (available here; registration required) has been sent to Marilyn Tavenner, CMS Administrator, seeking a six-month publication delay as required by the Open Payments System established under the Physician Payments Sunshine Act (which was passed as part of the Affordable Care Act). For industry, the challenge is to properly aggregate spending on events and "items of value" for physicians, as well as funding for research and related engagements. For physicians, the challenge will be to verify what is being reported about them.
“Fundamentally, we have no issue with efforts to increase transparency in the interactions between physicians and industry,” says the American Medical Assn. “However, we have a number of serious concerns regarding how the Open Payments System has been implemented.” AMA cites the delay in CMS issuing registration instructions for physicians into the system (so that they can review the data about them); a cumbersome registration process; procedural rulings for how educational activities and medical publications are covered; and industry’s ability (as determined by CMS) to have final say on data disputes.
AMA was joined by 61 other physician professional groups, and the medical associations of 48 states and the District of Columbia (for whatever reason, Alaska and Wisconsin didn’t sign on).
Information about the Open Payments System is front and center on AMA’s website homepage, and the association has developed a “Sunshine Act toolkit” to assist its members. Several media organizations—including ProPublica, an investigative journalism enterprise that started a “Dollars for Docs” information service several years ago, are eagerly waiting to see what the data will reveal.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.